Laura Palmeri

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 795 citations · Full text

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Elena Ardini, Roberta Bosotti et al. · JNCI Journal of the National Cancer Institute · 2015 · 245 citations · Full text

Radiation Oncology, Systems Biology, Oncology +15

Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.

Filippo de Braud, Monica Niger, Silvia Damian et al. · Journal of Clinical Oncology · 2015 · 53 citations

Pathology, Metronomic Chemotherapy, Advanced Solid Tumors +17

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site

S. Palmeri, Vito Lorusso, Laura Palmeri et al. · Cancer · 2006 · 51 citations · Full text